A method of enriching a population of stem cells for hematopoietic progenitors, the method comprising: a. inducing hematopoietic differentiation in a population of human embryonic stem cells or human induced pluripotent stem cells, comprising: (i)culturing the population with BMP4, between days 0 and 4 of hematopoietic differentiation induction; and/or (ii) culturing the population with bFGF, between days 1 and 8; and/or (iii) culturing the population with at least one of VEGF, DKK, IL-6 and IL-11, and/or a combination thereof, between days 3 and 13, or between days 4 and 9; and/or (iv) culturing the population with at least one of SCF and EPO, between days 4 and 13, or between days 6 and 9; and/or (v) culturing the population with at least one of TPO, Flt-3 and IL-3, and/or a combination thereof, between days 6 and 13, or between days 8 and 9; and inhibiting activin/nodal signaling comprising culturing the population with an activin/nodal inhibitor from day 2 to day 4, b. sorting the induced population at day 6 to day 13 by flow cytometry based on expression of CD43 and at least one of CD34, CD31 and CD144; and c. selecting a fraction that is at least one of CD34 + CD43 -, CD31 + CD43 - and CD144 + CD43 -; wherein: (i) inducing hematopoietic differentiation is conducted serum free; and (ii) inducing hematopoietic differentiation is conducted stroma free. a. inducing hematopoietic differentiation in a population of human embryonic stem cells or human induced pluripotent stem cells, comprising: (i)culturing the population with BMP4, between days 0 and 4 of hematopoietic differentiation induction; and/or (ii) culturing the population with bFGF, between days 1 and 8; and/or (iii) culturing the population with at least one of VEGF, DKK, IL-6 and IL-11, and/or a combination thereof, between days 3 and 13, or between days 4 and 9; and/or (iv) culturing the population with at least one of SCF and EPO, between days 4 and 13, or between days 6 and 9; and/or (v) culturing the population with at least one of TPO, Flt-3 and IL-3, and/or a combination thereof, between days 6 and 13, or between days 8 and 9; and inhibiting activin/nodal signaling comprising culturing the population with an activin/nodal inhibitor from day 2 to day 4, (i)culturing the population with BMP4, between days 0 and 4 of hematopoietic differentiation induction; and/or (ii) culturing the population with bFGF, between days 1 and 8; and/or (iii) culturing the population with at least one of VEGF, DKK, IL-6 and IL-11, and/or a combination thereof, between days 3 and 13, or between days 4 and 9; and/or (iv) culturing the population with at least one of SCF and EPO, between days 4 and 13, or between days 6 and 9; and/or (v) culturing the population with at least one of TPO, Flt-3 and IL-3, and/or a combination thereof, between days 6 and 13, or between days 8 and 9; and (i)culturing the population with BMP4, between days 0 and 4 of hematopoietic differentiation induction; and/or (ii) culturing the population with bFGF, between days 1 and 8; and/or (iii) culturing the population with at least one of VEGF, DKK, IL-6 and IL-11, and/or a combination thereof, between days 3 and 13, or between days 4 and 9; and/or (iv) culturing the population with at least one of SCF and EPO, between days 4 and 13, or between days 6 and 9; and/or (v) culturing the population with at least one of TPO, Flt-3 and IL-3, and/or a combination thereof, between days 6 and 13, or between days 8 and 9; and inhibiting activin/nodal signaling comprising culturing the population with an activin/nodal inhibitor from day 2 to day 4, b. sorting the induced population at day 6 to day 13 by flow cytometry based on expression of CD43 and at least one of CD34, CD31 and CD144; and c. selecting a fraction that is at least one of CD34 + CD43 -, CD31 + CD43 - and CD144 + CD43 -; (i) inducing hematopoietic differentiation is conducted serum free; and (ii) inducing hematopoietic differentiation is conducted stroma free.